Fundamental Analysis of United Therapeutics Corp. - Growth / Value Index
UTHR - Valuation Highlights
Valuation Analysis
Undervalued - Price to Intrinsic Value of 0.096
Price to Earning Ratio is 12.76 and EV to EBITDA is 8.24 suggesting company is undervalued.
Tremendous increasing in Book Value last 3 year
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 12.97 | 15.15 | -17.17 % | |
Price to Book | 2.47 | 2.28 | -17.87 % | 2.55 |
Price to Sales | 5.45 | 6.18 | -9.98 % | |
Enterprise Value to EBITDA Multiple | 8.38 | 13.01 | 2.37 % |
UTHR - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Good Score of 79.38
Gives Dividend Yield of 6.35 %
Earning Yield of 7.84 %
Excellent Net Margin for last 3 years
Excellent QoQ /QoQ FY EPS growth
Company Earning excess return
During the past twelve months, the company has given a strong Net Margin of 42.05%
All key Trailing Twelve Months Margin growing by 15 %
Piotroski F Score - Stable Value of 5.0
Annual Net Profit in last 3 years is trending up
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
Steady Growth in EPS for last four quarters
Good Return On Capital Employed of 13.46
Good Return on Equity of 19.05% is achieved by the company
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 19.05 | 15.03 | -0.843 % | 5.74 |
Return On Asset | 15.58 | 12.55 | 4.34 % | 4.72 |
Net Profit Margin | 42.05 | 40.82 | 8.68 % | 45.24 |
Operating Profit Margin | 50.31 | 49.92 | -1.34 % | 52.57 |
EBITDA Margin | 55.70 | 45.77 | -14.31 % | 62.99 |
Highlights
Market Cap | 12167.96 M |
Enterprise Value | 11660.26 M |
Price/Book TTM | 2.47 |
Outstanding Share | 44366.50 K |
Float/ Outstanding Share | 91.61% |
Dividend Yield | 6.35 % |
Share Holding
Guru Numbers
Price/Graham No | 1.15 |
Peter Lynch Ratio | 1.60 |
Piotroski F Score | 5.00 |
Altman Z Score | 8.56 |
Sloan Ratio | -0.0078 |
Peter Lynch Fair Value | 0 |
UTHR - Growth Highlights
Growth Analysis
Short term positive trend in total sale and net profit
Tremendous increasing trend in total sale last 3 year
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Poor Score of 26.72
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 2498.30 M | 13.84 % | 10.25 % |
Gross Profit | 2220.20 M | 9.77 % | 11.24 % |
EBITDA | 1391.50 M | 2.45 % | 31.68 % |
Net Profit | 1050.50 M | 23.72 % | 41.23 % |
EPS | 21.15 | 20.73 % | NA |
UTHR - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 85.94
Altman Z Score of 8.46 suggests good Stability
Debt to equity ratio has decreased and is lowest in last three years
Cash ratio of 3.72
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.117 | -29.87 % | 0.112 |
Cash Ratio | 3.72 | -55.00 % | |
Quick Ratio | 4.28 | -55.24 % | 3.64 |
Shareholders Equity | 83.50 | 5.23 % | |
Debt to EBITDA | 0.694 | -10.31 % |
Historical Valuation Ratios of United Therapeutics Corp.
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of United Therapeutics Corp.
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of United Therapeutics Corp.
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of United Therapeutics Corp.
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)